Institutional shares held 166 Million
855K calls
350K puts
Total value of holdings $2.37B
$12.3M calls
$5.02M puts
Market Cap $2.32B
161,843,008 Shares Out.
Institutional ownership 102.26%
# of Institutions 326


Latest Institutional Activity in ACAD

Top Purchases

Q1 2025
Assenagon Asset Management S.A. Shares Held: 3.66M ($52.6M)
Q1 2025
Allspring Global Investments Holdings, LLC Shares Held: 310K ($4.45M)
Q1 2025
Rhumbline Advisers Shares Held: 353K ($5.06M)
Q1 2025
Illinois Municipal Retirement Fund Shares Held: 72.1K ($1.03M)
Q1 2025
State Of Alaska, Department Of Revenue Shares Held: 68.2K ($979K)

Top Sells

Q1 2025
Sg Americas Securities, LLC Shares Held: 18.2K ($260K)
Q1 2025
Gamma Investing LLC Shares Held: 3.51K ($50.4K)
Q1 2025
Parallel Advisors, LLC Shares Held: 107 ($1.54K)
Q4 2024
Rtw Investments, LP Shares Held: 8.71M ($125M)
Q4 2024
State Street Corp Shares Held: 4.52M ($64.9M)

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.


Insider Transactions at ACAD

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
287K Shares
From 14 Insiders
Grant, award, or other acquisition 137K shares
Exercise of conversion of derivative security 150K shares
Sell / Disposition
111K Shares
From 5 Insiders
Open market or private sale 111K shares

Track Institutional and Insider Activities on ACAD

Follow ACADIA PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACAD shares.

Notify only if

Insider Trading

Get notified when an Acadia Pharmaceuticals Inc insider buys or sells ACAD shares.

Notify only if

News

Receive news related to ACADIA PHARMACEUTICALS INC

Track Activities on ACAD